Logo image of ALPHI.PA

FACEPHI BIOMETRIA SA (ALPHI.PA) Stock Fundamental Analysis

EPA:ALPHI - Euronext Paris - Matif - ES0105029005 - Common Stock - Currency: EUR

2.45  0 (0%)

Fundamental Rating

3

Taking everything into account, ALPHI scores 3 out of 10 in our fundamental rating. ALPHI was compared to 102 industry peers in the Software industry. Both the profitability and financial health of ALPHI have multiple concerns. While showing a medium growth rate, ALPHI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALPHI has reported negative net income.
ALPHI had a positive operating cash flow in the past year.
In the past 5 years ALPHI reported 4 times negative net income.
In multiple years ALPHI reported negative operating cash flow during the last 5 years.
ALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

ALPHI has a Return On Assets of -17.87%. This is in the lower half of the industry: ALPHI underperforms 78.43% of its industry peers.
ALPHI has a worse Return On Equity (-46.29%) than 78.43% of its industry peers.
Industry RankSector Rank
ROA -17.87%
ROE -46.29%
ROIC N/A
ROA(3y)-7.96%
ROA(5y)-7.7%
ROE(3y)-20.17%
ROE(5y)-18.66%
ROIC(3y)N/A
ROIC(5y)N/A
ALPHI.PA Yearly ROA, ROE, ROICALPHI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a Gross Margin value of 51.01%, ALPHI is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of ALPHI has declined.
ALPHI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.69%
GM growth 5Y-11.48%
ALPHI.PA Yearly Profit, Operating, Gross MarginsALPHI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

3

2. Health

2.1 Basic Checks

ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPHI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALPHI has more shares outstanding
ALPHI has a better debt/assets ratio than last year.
ALPHI.PA Yearly Shares OutstandingALPHI.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ALPHI.PA Yearly Total Debt VS Total AssetsALPHI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that ALPHI is in the distress zone and has some risk of bankruptcy.
ALPHI's Altman-Z score of 1.03 is on the low side compared to the rest of the industry. ALPHI is outperformed by 69.61% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that ALPHI is not too dependend on debt financing.
ALPHI has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. ALPHI outperforms 80.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.03
ROIC/WACCN/A
WACC9.2%
ALPHI.PA Yearly LT Debt VS Equity VS FCFALPHI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 1.08 indicates that ALPHI should not have too much problems paying its short term obligations.
The Current ratio of ALPHI (1.08) is worse than 63.73% of its industry peers.
ALPHI has a Quick Ratio of 1.08. This is a normal value and indicates that ALPHI is financially healthy and should not expect problems in meeting its short term obligations.
ALPHI's Quick ratio of 1.08 is on the low side compared to the rest of the industry. ALPHI is outperformed by 62.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
ALPHI.PA Yearly Current Assets VS Current LiabilitesALPHI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALPHI have decreased strongly by -51.15% in the last year.
Looking at the last year, ALPHI shows a quite strong growth in Revenue. The Revenue has grown by 14.80% in the last year.
ALPHI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.65% yearly.
EPS 1Y (TTM)-51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-686.71%
Revenue 1Y (TTM)14.8%
Revenue growth 3Y29.94%
Revenue growth 5Y28.65%
Sales Q2Q%11.54%

3.2 Future

The Earnings Per Share is expected to grow by 89.42% on average over the next years. This is a very strong growth
ALPHI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.45% yearly.
EPS Next Y45.45%
EPS Next 2Y89.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.7%
Revenue Next 2Y25.46%
Revenue Next 3Y15.33%
Revenue Next 5Y11.45%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALPHI.PA Yearly Revenue VS EstimatesALPHI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
ALPHI.PA Yearly EPS VS EstimatesALPHI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2022 2023 2024 2025 2026 0 0.1 -0.1 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALPHI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPHI.PA Price Earnings VS Forward Price EarningsALPHI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPHI.PA Per share dataALPHI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ALPHI's earnings are expected to grow with 89.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALPHI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FACEPHI BIOMETRIA SA

EPA:ALPHI (6/17/2025, 7:00:00 PM)

2.45

0 (0%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)10-20 2025-10-20
Inst Owners19.23%
Inst Owner ChangeN/A
Ins Owners5.59%
Ins Owner ChangeN/A
Market Cap63.16M
Analysts82.86
Price Target2.51 (2.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.12%
PT rev (3m)36.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF 87.19
P/B 3.29
P/tB 8.54
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.03
OCFY1.15%
SpS1.12
BVpS0.74
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.87%
ROE -46.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.01%
FCFM N/A
ROA(3y)-7.96%
ROA(5y)-7.7%
ROE(3y)-20.17%
ROE(5y)-18.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.69%
GM growth 5Y-11.48%
F-Score5
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.96%
Cap/Sales 18.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z 1.03
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)134.96%
Cap/Depr(5y)175.34%
Cap/Sales(3y)22.22%
Cap/Sales(5y)23.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-686.71%
EPS Next Y45.45%
EPS Next 2Y89.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.8%
Revenue growth 3Y29.94%
Revenue growth 5Y28.65%
Sales Q2Q%11.54%
Revenue Next Year10.7%
Revenue Next 2Y25.46%
Revenue Next 3Y15.33%
Revenue Next 5Y11.45%
EBIT growth 1Y-23.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year376.5%
EBIT Next 3Y89.21%
EBIT Next 5Y63.37%
FCF growth 1Y49.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.1%
OCF growth 3YN/A
OCF growth 5YN/A